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Abstract Peptide receptor radionuclide therapy (PRRNT) is a
molecularly targeted radiation therapy involving the systemic
administration of a radiolabelled peptide designed to target with
high affinity and specificity receptors overexpressed on
tumours. PRRNT employing the radiotagged somatostatin re-
ceptor agonists 90Y-DOTATOC ([90Y-DOTA0,Tyr3]-octreotide)
or 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3,Thr8]-octreotide or
[177Lu-DOTA0,Tyr3]-octreotate) have been successfully used
for the past 15 years to target metastatic or inoperable neuro-
endocrine tumours expressing the somatostatin receptor
subtype 2. Accumulated evidence from clinical experience
indicates that these tumours can be subjected to a high absorbed
dose which leads to partial or complete objective responses in
up to 30 % of treated patients. Survival analyses indicate that
patients presenting with high tumour receptor expression at
study entry and receiving 177Lu-DOTATATE or 90Y-DOTA-
TOC treatment show significantly higher objective responses,
leading to longer survival and improved quality of life. Side
effects of PRRNT are typically seen in the kidneys and bone
marrow. These, however, are usually mild provided adequate
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protective measures are undertaken. Despite the large body of
evidence regarding efficacy and clinical safety, PRRNT is still
considered an investigational treatment and its implementation
must comply with national legislation, and ethical guidelines
concerning human therapeutic investigations. This guidance
was formulated based on recent literature and leading experts’
opinions. It covers the rationale, indications and contraindica-
tions for PRRNT, assessment of treatment response and patient
follow-up. This document is aimed at guiding nuclear
medicine specialists in selecting likely candidates to receive
PRRNT and to deliver the treatment in a safe and effective
manner. This document is largely based on the book pub-
lished through a joint international effort under the auspices
of the Nuclear Medicine Section of the International Atom-
ic Energy Agency.
Keywords Peptide receptor radionuclide therapy . PRRNT .
PRRNT, neuroendocrine tumours, guideline/s, renal protection
Purpose
This guidance document is aimed at assisting and guiding
nuclear medicine specialists in:
1. Assessing patients with neuroendocrine tumours (NETs)
for their eligibility to undergo treatment with 90Y- or
177Lu-radiolabelled somatostatin analogues.
2. Providing guidance on performing peptide receptor ra-
dionuclide therapy (PRRNT) and implementing this
treatment in a safe and effective manner.
3. Understanding and evaluating the outcome of PRRNT,
namely treatment results and possible side effects in-
cluding both renal and haematological toxicities.
A committee of international experts was assembled
under the auspices of the International Atomic Energy
Agency (IAEA), in cooperation with the EANM Thera-
py, Oncology and Dosimetry Committees and with the
Society of Nuclear Medicine and Molecular Imaging.
They worked together to create this guidance document
on the use of somatostatin analogue-based PRRNT. This
guidance document was compiled taking into account
recent literature and experts’ opinion.
Regulatory issues
Applicable in all countries Clinicians involved in unsealed
source therapy must be knowledgeable about and compliant
with all applicable national and local legislation and
regulations.
Applicable in the USA The radiopharmaceuticals used for
the diagnostic and therapeutic procedures addressed in this
guidance document are not approved by the Food and Drug
Administration (FDA) in the USA. Therefore in the USA
these procedures should be performed only by physicians
enrolled in an investigational protocol pursuant to a valid
Investigational New Drug application or Radioactive Drug
Research Committee approval and under the purview of an
appropriate institutional review board.
Background information and definitions
Definitions
PRRNT PRRNT (or PRRT) involves the systemic
administration of a specific well-defined
radiopharmaceutical composed of a β-
emitting radionuclide chelated to a pep-
tide for the purpose of delivering cyto-
toxic radiation to a tumour. The
oligopeptides are designed to target cel-
lular proteins, commonly cell surface
receptors, such as the somatostatin recep-
tor (sstr) subtype 2 (sstr2) that is overex-
pressed on the cell surface of NETs in a
tumour-specific fashion, thereby ensuring
a high level of specificity in the delivery
of the radiation to the tumour. Hence,
PRRNT is a molecularly targeted radia-
tion therapy, and thus is distinct from ex-
ternal beam radiation therapy.
Somatostatin The naturally occurring somatostatin
molecule is an oligopeptide comprising
either 14 or 28 amino acids with a
limited half-life in blood due to rapid
enzymatic degradation. Somatostatin
exerts an antisecretory endocrine and
exocrine effect in addition to tumour
cell-growth inhibition. Stabilized ana-
logues of somatostatin (SSA) show
prolonged duration of action [1].
Somatostatin
receptors
In humans five sstr subtypes have been
identified. Each sstr is a transmembrane
molecule weighing approximately
80 kDa. Somatostatin exerts its action by
inhibiting G-protein-dependent 3′,5′-
cyclic monophosphate (cAMP) formation
in a dose-dependent manner at
subnanomolar concentrations. Sstr2 is
overexpressed in NETs. Sstr2 is the key
target molecule for both cold and
radiolabelled SSA. Upon binding to its
receptor, the complex (SSA-sstr) under-
goes cellular internalization thereby
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enhancing the therapeutic effect of the
radiolabelled drug [2].
Yttrium-90 The radiometal 90Y is a pure β-emitting
isotope with a physical half-life of 64 h.
The maximum and mean β-particle ener-
gies are 2.28 MeV and 0.934 MeV, re-
spectively. The maximum and mean β-
particle penetration depths in soft tissue
are 11 mm and 3.9 mm, respectively.
Lutetium-177 177Lu is a β- and γ-emitting radionuclide
with a physical half-life of 162 h (6.73
days). Compared to 90Y, 177Lu has lower
maximum and mean β-particle energies
(0.498 MeVand 0.133 MeV, respectively).
These translate to maximum and mean
soft-tissue penetration depths of 1.7 mm
and 0.23 mm, respectively. 177Lu has two
main gamma emission lines: 113 keV (6 %
relative abundance) and 208 keV (11 %
relative abundance). The latter properties
of 177Lu allow posttreatment imaging and
dosimetry assessments.
DOTATOC DOTATOC is a derivatized somatostatin
analogue peptide. DOTATOC is the
abbreviated form of [DOTA0,Tyr3]-
octreotide, where DOTA stands for the
bifunctional chelating molecule 1,4,7,10-
tetraazacyclo-dodecane-1,4,7,10-
tetraacetic acid, and Tyr3-octreotide is the
modified octreotide. This peptide shows a
high affinity for sstr2 (IC50 14±2.6 nM),
but lower affinities for sstr5 (IC50 393±84
nM) and sstr3 (IC50 880±324 nM) [3].
DOTATATE DOTATATE is also a derivatized
somatostatin analogue peptide.
DOTATATE is the abbreviated form of
[DOTA0,Tyr3,Thr8]-octreotide or
[DOTA0,Tyr3]-octreotate, and DOTA
stands for the bifunctional metal-
chelating molecule. This peptide shows
a six- to ninefold higher affinity for
sstr2 (IC50 1.5±0.4 nM) than DOTA-
TOC, but has no affinity for either
sstr5 (IC50 547±160 nM) or sstr3
(IC50 >1,000 nM) [4].
Background
NETs have proven to be ideal neoplasms for PRRNT, as the
majority of these slow-growing malignancies overexpress
sstrs. Appropriate candidates for PRRNT are patients present-
ing with well-differentiated or moderately differentiated neu-
roendocrine carcinomas, defined as NETs of grade 1 or 2
according to the WHO classification of 2010 [5]. The inci-
dence of NETs has been rising over the past 30 years, partic-
ularly those arising from the midgut and pancreas [6]. The
incidence of NETs in the USA rose from 10.9 to 52.4 per
million between 1973 and 2004 (SEER database). NETs can
occur in children and young adults, being diagnosed as early as
at the age of 5 years, while their incidence increases with age.
The clinical presentation may vary depending on the site of
tumour origin. About 72 % of NETs arise in gastrointestinal
structures, 25% are bronchopulmonary in origin, and less than
5 % arise at other sites (e.g. thymus, breast and genitourinary
system). Frequently, these tumours are discovered when meta-
static or locally advanced and therefore inoperable. NETs can
be either functioning or nonfunctioning in nature. Functioning
tumours are associated with clinical syndromes, such as the
carcinoid syndrome (due to the release of serotonin). Other
secreting tumours include insulinomas (inducing hypoglycae-
mia), gastrinomas (inducing Zollinger-Ellison syndrome),
VIPomas (associated with the watery diarrhoea, hypokalaemia
and achlorhydria syndrome; WDHA syndrome).
Anatomical imaging of NETs should be as detailed
and extensive as possible to provide accurate informa-
tion about site and extent of the primary tumour, and
the location and extent of regional and distant metasta-
ses. An exact assessment of liver metastases and degree
of liver involvement using ultrasonography, CT or MRI
is central for accurate staging and for assessing the
response to treatment [7].
Functional imaging procedures applying sstr imaging
using 111In-pentetreotide (OctreoScan) with SPECT or
PET with 68Ga-labelled SSA, combined with morpho-
logical imaging procedures, are used to collect essential
information for staging, assessing sstr status and making
decisions on the most appropriate therapy regimens [8,
9]. Serial morphological examinations are mandatory to
monitor therapy and detect recurrent disease. Emerging
data indicate that 18F-FDG PET may have additional
prognostic value [10]. This information, however, needs
validation in larger studies.
Multiple treatment approaches are now available for
patients presenting with metastatic disease, considering re-
cently introduced molecular targeted therapies and multi-
modality treatment options. For the choice of the most
appropriate treatment, information regarding anatomical lo-
cation and local invasion of adjacent structures, tumour
functionality, sstr status, histological grading and staging
are required to facilitate the decision-making process within
the multidisciplinary tumour board. If the disease is restrict-
ed to the liver, surgical and locoregional approaches should
be considered primarily. Chemotherapy is appropriate for
highly proliferating NETs and pancreatic NETs, keeping in
mind the fact that the vast majority of NETs are rather
insensitive to this treatment.
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Treatment options in NETs
Patients with NETs may present with local tumours, with or
without regional or distant metastases. The common site of
metastasis is the liver. These tumours may remain clinically
silent until a significant liver tumour burden is present.
Therapeutic options include surgery, SSA, interferon, che-
motherapy, molecularly targeted agents, locoregional thera-
pies and PRRNT. Supportive palliative care and pain control
also play an important role in patient management. These
options are not mutually exclusive and, for the most part, are
interchangeable. Options of care, including PRRNT, should
be chosen and implemented in a correct sequence by an
experienced multidisciplinary team. This approach should
provide the highest benefit while minimizing the risks and
side effects and ensuring the best quality of life achievable
for the patient. Surgery with curative intent should always
be performed whenever feasible; in selected cases, and
within a multidisciplinary approach, PRRNT may be bene-
ficial as a neoadjuvant therapy to render a patient accessible
to surgery. For functionally active tumours, cytoreductive
strategies, e.g. transarterial chemoembolization (TACE),
transarterial embolization (TAE), radiofrequency ablation
(RFA) and other techniques such as selective internal radi-
ation therapy (SIRT), should always be considered with the
intention of ameliorating clinical symptoms. The optimal
management of NETs is early surgical removal prior to the
development of regional or distant metastases. Unfortunate-
ly, many patients are diagnosed with metastatic disease,
when complete eradication of their tumours will not be
possible. Removal of the primary tumour is indicated to
prevent complications such as bleeding or small-bowel ob-
struction. Even in the presence of liver metastases, removal
of the primary tumour has several advantages and seems to
have a positive prognostic impact on survival [11–14]. Sol-
itary or isolated liver metastases can be surgically removed,
while a more diffuse liver infiltration is usually treated using
a locoregional approach.
Locoregional approaches or local ablative therapies target
predominantly liver metastases aiming at achieving local
tumour control and alleviating functional secretory syn-
dromes. Different techniques are applied depending on in-
dividual findings (number size and distribution of liver
lesions, their morphology, focal or diffuse, and their vascu-
larization), functional activity of the NET and locally avail-
able expertise. In an individual with few liver lesions with a
preferably resected primary lesion, liver lesions can be trea-
ted by surgical resection with or without RFA or laser-
induced interstitial thermoablation. In those with multifocal
or diffuse liver disease causing a high tumour load, TACE
and TAE are the preferred choices [15, 16]. Local emboli-
zation techniques are particularly useful when treating
patients with functionally active liver metastases. Following
TACE, symptomatic response rates of 60–95 % and bio-
chemical response rates of 50–90 % are achieved and radio-
logical response of 33–80 % have been reported [17–19].
Response duration is between 18 and 24 months. Similar
response rates are achieved with TAE alone [16]. In general,
the procedure may require more than one treatment session
to ensure effectiveness and consolidation of the treatment
and to minimize the risk of complications.
The recently introduced SIRT has shown variable re-
sponse rates among individual centres [20]. Prospective
studies are however lacking. In a single prospective study
in 34 patients the objective response rate was 50 % [19].
Given the lack of comparative studies of the different tech-
niques used for local ablative and locoregional therapies, the
choice of technique will be highly dependent on the physi-
cians’ experience in the different centres and on individual
criteria such as number, size, vascularization and distribu-
tion of the lesions.
Among the medical treatments, octreotide and lanreotide
are the two most used sstr agonists. They play an essential
role in the control of both symptomatic and asymptomatic
NETs and should be regarded as first-line therapy. SSA can
be used with virtually all of the other therapeutic options
available. As the vast majority (87–92 %) of NETs express
sstr2, patients should always be offered this therapy along-
side other concurrent therapeutic options, and for supportive
care. Long-acting SSA possess secretory inhibiting action,
and are approved for alleviating the symptoms of the carci-
noid syndrome, such as flushing and diarrhoea or bronchial
obstruction, and to prevent carcinoid crisis. It is reported
that treatment with SSA may control the clinical syndrome
in 40–90 % of patients subject to tumour load and dosage
[21, 22]. Nevertheless, patients may become refractory to
syndrome control, and need incremental dosage increases of
SSA. However, most patients with tumour progression re-
quire an additional treatment, including the use of PRRNT.
The recent PROMID study conducted in Germany showed
the effectiveness of long-acting SSA as an antiproliferative
therapeutic agent in midgut NET. In this study, time to
tumour progression in patients given octreotide LAR
30 mg intramuscularly monthly was more than double that
in patients receiving only placebo (6.0 vs. 14.3 months). The
NCCN guidelines and very recently the ENETS guidelines
have added octreotide as an option for antiproliferative
treatment [23, 24].
Interferon-alpha (IFN-α) has been used for treating
patients with NETs, especially those with the carcinoid
syndrome, for more than 25 years. It is considered the main
antisecretory drug used for the treatment of functional
tumours [25]. IFN-α effectively reduces hypersecretion-
related symptoms in patients with carcinoid syndrome in a
similar manner to SSA. Partial tumour growth responses are
also observed in 10–15 % of patients with malignant
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carcinoids, and stabilization in 39 %. IFN-α has also been
demonstrated to be effective in endocrine pancreatic
tumours [26]. The very common side effect of IFN-α,
namely a ’flu-like syndrome, limits both the use of high
dosages and the duration of treatment due to intolerance
forcing its interruption. Systemic chemotherapy is effective
in some patients, especially those with poorly differentiated
NET/neuroendocrine carcinoma (grade 3, WHO 2010) or
progressive NET of the pancreas. However, in well-
differentiated midgut NETs/NETs (grade 1/2, WHO 2010)
the response rates to chemotherapy are low (7–20 %) and a
survival advantage has not been demonstrated [27, 28]. The
standard treatment for neuroendocrine carcinoma (grade 3)
is cisplatin and etoposide. The response rate with this com-
bination is 42–67 %, and its duration is often short, ranging
from 8 to 9 months [32]. The combination of irinotecan and
cisplatin [29] or FOLFOX chemotherapy (5-fluorouracil or
capecitabine and oxaliplatin) may be an alternative [30].
PRRNT is very rarely a suitable treatment option for neuro-
endocrine carcinoma (grade 3), because of the low expres-
sion of sstr but it may be considered following the failure of
chemotherapy and if 111In-pentetreotide (OctreoScan) or
68Ga-DOTATOC/DOTATATE PET/CT demonstrates mod-
erate to high sstr expression.
Systemic chemotherapy based on streptozotocin (Zano-
sar, STZ) is considered a standard therapy for progressive
pancreatic NETs with low or moderate proliferative capac-
ity. Combinations of STZ and 5-fluorouracil and/or doxoru-
bicin have been shown to lead to partial remission rates of
35–40 % [31–33]. Recent phase II studies have shown
efficacy of temozolomide based chemotherapy either with
antiangiogenic drugs or capecitabine [34, 35]. Standards of
care for the use of chemotherapy have been defined by
ENETS [36]. In recent years, the efficacy of molecular
targeted therapies for treating NETs has been assessed in
clinical trials. These therapies include angiogenesis inhib-
itors, single or multiple tyrosine kinase inhibitors and the
novel SSA analogue pasireotide, for which clinical trials are
ongoing. The drugs with the highest evidence of efficacy are
sunitinib and everolimus (RAD-001). Both lead to extension
of progression-free survival (PFS) of patients with advanced
pancreatic NET. For everolimus, an mTOR inhibitor, there
is evidence of efficacy in controlling NET arising from other
sites associated with the carcinoid syndrome [37]. The most
developed antiangiogenic drugs are sunitinib and the anti-
VEGF antibody bevacizumab. In a phase II study bevacizu-
mab in combination with octreotide LAR led to partial
tumour remission in 18 % of patients and stable disease in
77 % [38]. A recent international phase III study of sunitinib
versus placebo in patients with progressive well-
differentiated endocrine pancreatic tumour was interrupted
prematurely due to the striking superiority of sunitinib evi-
dent by a PFS of 11.1 vs. 5.5 months [39]. The objective
remission rate was less than 10 %. The drug was recently
approved by the US FDA and the European Medicines
Agency for the treatment of advanced and progressive
well-differentiated pancreatic NETs.
Everolimus has been studied in more than 1,000 patients
with NET and has been included in several clinical trials
(RADIANT-1, RADIANT-2, RADIANT-3 trials, RAM-
SETE trial). Antitumour activity of everolimus has been
confirmed in RADIANT-1 in patients with progressive
metastatic pancreatic NETs after failure of at least one line
of cytotoxic chemotherapy. The trial studied 160 patients
divided into two groups with or without monthly intramus-
cular octreotide acetate therapy. The combination therapy
group showed significantly longer PFS (16.7 vs. 9.7 months)
[40]. The efficacy of everolimus has been confirmed in a
large international placebo-controlled trial including 410
patients with progressive pancreatic NET (RADIANT-3)
[41]. Everolimus significantly reduced the risk of disease
progression and led to a prolongation of PFS by 6.4 months
(11 vs. 4.6 months) compared to placebo. Objective tumour
response was low (4.8 % partial remissions). Disease control
rate (partial response + stable disease) was, however, higher
with everolimus than with placebo with best supportive care
(77.7 % vs. 52.7 %). Side effects were rarely grade 3 or 4;
the most frequently reported side effects included stomatitis,
anaemia and hyperglycaemia. In May 2011 the US FDA
approved everolimus for the treatment of progressive NETs
of pancreatic origin in patients with nonresectable, locally
advanced, or metastatic disease.
In the global supportive approach to the patient, and
when delivering PRRNT, nutrition and pain control are an
essential component of care. Treatment of pain in patients
with NET follows the general principles followed in adult
and paediatric oncology [42]. Effective treatment of NETs,
such as PRRNT, may alleviate pain, including bone pain.
Treatment of painful bone metastasis is also mandatory with
the administration of bisphosphonates as supportive therapy.
PRRNT a historical overview
PRRNT using radiolabelled octreotide was first attempted in
the 1990s. The initial phase I trial investigated the safety and
efficacy of using high activities of the diagnostic compound
111In-octreotide as a therapeutic radiopharmaceutical. The
results in terms of clinical efficacy were attributed to the effect
of intracellular emission of the Auger and conversion elec-
trons by 111In following the internalization of the peptide–
receptor complex. Partial remissions were exceptional, and
furthermore three patients developed leukaemia or myelodys-
plastic syndrome from the group receiving the highest cumu-
lative dose (90–100 GBq) [43]. In Europe, 111In-pentetreotide
was abandoned as a therapy option in favour of the more
efficient β emitters 90Y and 177Lu. 111In-pentetreotide is,
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however, still used by some in the USAmainly due to the lack
of availability ofβ-emitting radiotracers. High-energyβ emit-
ters, such as 90Y with a longer β range in soft tissue, were
considered more promising for the treatment of bulky tumour.
A novel analogue, Tyr3-octreotide, with a similar affinity
profile for sstrs, was developed. Linked to a macrocyclic
chelator (DOTA), it allows simple and stable radiolabelling
of 111In and 90Y to [DOTA0,Tyr3]-octreotide (90Y-DOTA-
TOC) [44]. PRRNT using 90Y-DOTATOC was first used in
1996 in a patient in Basel, Switzerland. The excellent subjec-
tive and objective response following several cycles of 90Y-
DOTATOC led to high expectations as to the therapeutic
potential of PRRNT in patients with NET. Since then other
centres worldwide have conducted clinical trials with 90Y-
DOTATOC [45]. Since the year 2000, octreotate (Tyr3,Thr8-
octreotide), a newer analogue with improved affinity for sstr2,
has been synthesized. The chelated analogue [DOTA0,Tyr3]-
octreotate (DOTATATE) can be labelled with the β- and γ-
emitting isotope 177Lu and has been used in clinical studies.
Indications and contraindications
Indications
PRRNT is indicated for the treatment of patients with
positive expression of sstr2, or metastatic or inoperable
NET [46–50]. Candidate patients for PRRNT using
radiolabelled somatostatin analogues are mainly those
with sstr2-expressing NET of the gastroenteropancreatic
and bronchial tracts, but may also include patients with
phaeochromocytoma, paraganglioma, neuroblastoma [51]
or medullary thyroid carcinoma [52–56]. The ideal can-
didates for PRRNT are those with well-differentiated
and moderately differentiated neuroendocrine carcinomas
defined as NET grade 1 or 2 according to the recent




& Severe acute concomitant illnesses.
& Severe unmanageable psychiatric disorder.
Relative
& Breast feeding (if not discontinued).
& Severely compromised renal function: for PRRNT with
a 90Y-labelled peptide age-adjusted normal renal func-
tion is essential. Patients with compromised renal func-
tion may still be considered for 177Lu-labelled peptide
treatment. For 177Lu-labelled peptide a mild to moderate
grade of renal impairment can be tolerated (e.g. creati-
nine ≤1.7 mg/dl). Glomerular filtration rate (GFR) and
tubular extraction rate (TER) should be at least 60 % of
mean age-adjusted normal values.
& Severely compromised bone marrow: noncompromised
haematological reserve should be present before
PRRNT. Suggested reference values are:
WBC<3,000/μl, with absolute neutrophil count <1,000/μl





The kidney is the dose-limiting organ at the activities
normally used for PRRNT. Side effects involving the
kidney and the bone marrow are mild if adequate renal
protection and fractionation are used. Renal function
should be assessed by means of laboratory tests (creat-
inine and BUN), or calculation of creatinine clearance
(e.g. Cockroft-Gault formula). Additional studies, e.g.
measurement of GFR with 24-h urine collection or
nuclear medicine methods (e.g. 99mTc-MAG3 with
TER determination, 99mTc-DTPA GFR or effective renal
plasma flow using hippuran), should be performed in
patients with risk factors for renal toxicity or with
compromised renal function, and in all children.
Aggravating conditions (caveats)
& Renal outflow obstruction, potentially leading to
hydronephrosis, and, ultimately, to loss of renal
function, should always be ruled out or otherwise
corrected before PRRNT.
& Previous myelotoxic chemotherapy and extended ex-
ternal beam irradiation fields to the bone marrow
(pelvis, spine), particularly if performed in the
weeks preceding the PRRNT, do increase the risk
of bone marrow failure after PRRNT. In doubtful
cases of haematological compromise, a bone marrow
biopsy might be indicated to assess bone marrow
status in pretreated patients and to assess the risk
when planning for multiple PRRNT cycles (e.g.
intervals between cycles). Depending on the amount
of 90Y-DOTATOC or 177Lu-DOTATATE activity
injected, persisting depressed platelets values follow-
ing prior PRRNT cycle(s) can impede the timing and
dosing of subsequent cycles.
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& A patient with pending liver failure should be consid-
ered with caution before being submitted to PRRNT.
Procedure
Pretherapy assessment
The availability of the following information is mandatory
when considering a patient for PRRNT:
& NET proven by histopathology (immunohistochemistry).
& High sstr expression determined by functional whole-
body imaging with 111In-pentetreotide (OctreoScan) or 68
Ga-DOTA-peptide PET/CT or immunohistochemistry.
The following criteria should be taken into consideration
when deciding whether or not to perform PRRNT.
& Karnofsky/Lansky performance status above 60 % or
ECOG performance status less than 2.
& Tumour differentiation, preferably grade 1/2.
& Tumour proliferation rate, preferably with a Ki-67/mitotic
index ≤20 %. In addition, the rate of tumour growth, as
determined by CTorMRI, could be considered. Note that,
in general, less-differentiated tumours showing high pro-
liferation rates are better candidates for chemotherapy.
Facility and personnel
PRRNT is still considered an investigational treatment and
its implementation must comply with national legislation
and local requirements, as well as with ethical principles
regarding human studies. The decision to provide PRRNT
should be taken within a multidisciplinary tumour board,
including all the specialists involved in the care of patients
with NET. The facility requirements will depend on national
legislation on the therapeutic use of radioactive agents. If
inpatient therapy is required by national legislation, the
treatment should take place in an approved facility. The
facility must have appropriate personnel, radiation safety
equipment, and procedures for waste management and han-
dling accidental contamination of the site or personnel.
90Y-DOTATOC or 177Lu-DOTATATE should be admin-
istered by appropriately trained medical staff with support-
ing nursing staff with a medical physics expert available.
Physicians responsible for treating patients should have a
general knowledge of the pathophysiology and natural history
of the respective diseases, should be familiar with alternative
forms of therapy, and should be able to closely liaise with
other physicians involved in managing the patients. Clinicians
involved in the utilization of unsealed radionuclide sources for
therapy must also be knowledgeable about and compliant with
applicable national legislation and local regulations.
Patient preparation
Renal protection
Together with the bone marrow, the kidneys are the critical
organs in PRRNT particularly when using 90Y-DOTATOC.
Proximal tubular reabsorption of the radiopeptide and subse-
quent retention in the interstitium result in excessive renal
irradiation. Nephrotoxicity may be aggravated by risk factors,
such as preexisting hypertension or diabetes mellitus [57]. To
counteract and reduce the high kidney retention of radiopep-
tides, positively charged amino acids, such as L-lysine and/or
L-arginine, are coinfused to competitively inhibit the proximal
tubular reabsorption of the radiopeptide. The coadministration
of these amino acids leads to a significant reduction in the
renal absorbed dose, which ranges from 9 % to 53 % [58].
Renal absorbed dose is further reduced by up to 39 % by
extending the infusion time of the amino acid solution over
10 h, and up to 65 % by extending the protection over 2 days
following radiopeptide administration, thereby covering the
renal elimination phase more efficiently [59, 60].
Amino acid protection protocols
Lysine and/or arginine should be diluted appropriately in
large volumes of normal saline in order to hydrate the
patient, unless the patient suffers from cardiac insufficiency
(e.g. carcinoid heart valve disease), in which case volume
overload, possibly leading to acute exacerbation of the con-
dition, should be avoided. Hyperosmotic solutions in partic-
ular should be avoided since they can induce dangerous
electrolyte imbalances that might lead to severe metabolic
acidosis and cardiac arrhythmias. An appropriate dilution is
25 g of amino acid in 1 l of normal saline.
Before beginning the amino acid infusion, appropriate
measures against nausea and vomiting should be undertaken
by administering an antiemetic (e.g. 5-HT3 antagonist, such as
granisetron) and/or a corticosteroid (e.g. dexamethasone).
Antiemetic can be repeated if needed. Amino acid infusion
should be started 30–60 min before administration of the
radiopeptide and should be maintained over 4 h. Particular
attention and care should be given to avoiding possible elec-
trolyte imbalance (hyperkalaemia and hypernatraemia), and
the consequent metabolic acidosis, that might lead to mild
nausea and vomiting [61]. These side effects should be man-
aged by hydrating the patient with normal saline and possibly
by repeating corticosteroid or antiemetic administrations.
Proposed amino acid protective schemes
1. Single-day 50-g protection protocol
A solution containing a 50-g cocktail of lysine and argi-
nine (25 g of lysine and 25 g of arginine) diluted in 2 l of
806 Eur J Nucl Med Mol Imaging (2013) 40:800–816
normal saline infused over 4 h, starting 30–60 min before
PRRNT.
2. Three-day 25-g protection protocol
During day 1, a cocktail of 25 g of lysine diluted in 1 l of
normal saline is infused over 4 h, starting 30–60 min before
the PRRNT. This is followed by the administration of a
12.5 g lysine solution in 500 ml of normal saline over 3 h
twice a day on the second and third day after therapy. This
protocol is aimed at maximizing renal protection while
minimizing the side effects of the amino acid infusion.
3. Three-day 50-g protection protocol
A 50-g solution of lysine and arginine (25 g/25 g) diluted
in 2 l normal saline infused over 4 h during the first day
starting 30–60 min before therapy. This is followed by the
administration of an additional 12.5 g lysine diluted in
500 ml of normal saline infused over 3 h twice a day on
day 2 and day 3 after therapy.
4. Single-day 50 g+Gelofusine
Renal uptake of radiolabelled somatostatin analogues can
in part be attributed to the receptor-mediated endocytic renal
transporter system involving megalin-mediated cubilin-
dependent endocytosis across the proximal epithelium.
Gelofusine, a succinylated bovine gelatin molecule com-
monly used as a plasma expander, can be administered to
further reduce kidney absorbed radiation dose (by about
45 %) through its interaction with the megalin/cubilin
receptor-mediated transporter system [62, 63]. There have
been some safety concerns about the use of Gelofusine
following the occurrence of allergic reactions, although mild
in most cases. Severe anaphylactoid reactions are described
in approximately 0.04 % [64, 65]. The treating physician
should be aware of these effects and be prepared to treat
them accordingly with antihistaminic drugs, corticosteroids
or epinephrine. A protection protocol consists of a cocktail
of 25 g lysine+25 g arginine diluted in 2 l of normal saline
infused over 4 h starting 30–60 min before therapy, and
Gelofusine infusion as a bolus of 1 ml/kg body weight over
10 min before therapy, followed by Gelofusine infusion at
0.02 ml/kg/min over 3 h after radiopeptide infusion. Due to
reported adverse immunogenic reactions, vital parameters
should be monitored during Gelofusine infusion [62].
Precautions in special clinical conditions In patients with
severe cardiac insufficiency, volume overload that might lead
to acute cardiac insufficiency and decompensation, should be
avoided. Therefore, formulations with lower amounts of ami-
no acids and hence lower volumes should be chosen (e.g. 25 g
of lysine or arginine diluted in a maximum of 1 l of normal
saline). In any case, a stringent monitoring regimen with
participation of a cardiologist is recommended. In patients
with preexisting nephrolithiasis, forced diuresis might mobi-
lize kidney stones leading to acute renal colic. These events
should be treated appropriately but, if possible, anticipated
and avoided by infusing lower volumes. Phlebitis associated
with the hyperosmolarity of the infused amino acid solution
may occur at the site of injection. This condition can be treated
with local vasoprotective creams.
Somatostatin analogue withdrawal
Somatostatin analogues are available as short-acting or
long-acting preparations. These should be discontinued pri-
or to PRRNT as they might interfere with receptor targeting.
The duration of interruption, however, depends on the half-
life of the analogue used. Withdrawal periods of 4–6 weeks
for long-acting release formulations and of at least 24 h for
short-acting formulations are considered good clinical prac-
tice. This topic is still a matter of debate [7, 8]. In practice a
long-acting release formulation is substituted by a short-
acting formulation 1 month prior to PRRNT.
Radiopharmaceutical and administration
Quality control
Both 90Y and 177Lu are trivalent metals; they form a highly
stable complex with the DOTA chelating molecule. “Sim-
ple” radiochemical purity (RP) testing to assess the fraction
of free radionuclide using thin layer chromatography or
solid phase extraction (using a Sep-Pak cartridge) is not
mandatory for commercially acquired therapeutic radiophar-
maceuticals. However, if such quality control is desired by
the end-user, it should be conducted by adequately trained
and qualified professionals. Applying this simple test, the
RP should not fall below 98 %. It is worth noting that a
more sophisticated method such as high-performance liquid
chromatography might reveal additional impurities, and thus
a RP of 98 % will be difficult to achieve. As to the amount
of peptide employed for an individual treatment cycle (sin-
gle infusion), the consensus is that for formulations labelled
with 177Lu the mass of peptide should be between 100 and
200 μg, and should not exceed 250 μg per patient dose,
while for carrier-free 90Y it should be between 100 and
150 μg per patient. It is common practice to add excess
sodium DTPA to the radiopharmaceutical prior to dispens-
ing because it binds free radiometals and facilitates their fast
renal clearance. The specific activity should not fall below a
certain value. 90Y is produced as a carrier-free radionuclide
from the parent radioisotope 90Sr with a theoretically max-
imum achievable specific activity close to 1,295 MBq/μg
(35 mCi/μg). Metal impurities, particularly iron, lead to a
significant lowering of the specific activity of the radiopep-
tide and can occasionally impede the labelling procedure.
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The radioisotope 177Lu is produced by a nuclear
reactor either via the direct or the indirect pathway;
the direct pathway involves the n-gamma irradiation of
an enriched 176Lu target. The indirect pathway involves
the irradiation 176Yb to produce the short-lived 177Yb
(T1/2 1.9 h) that decays to
177Lu. The latter method
avoids the production of the long-lived 177mLu (T1/2
60 days). Few high neutron-flux reactors are capable
of producing 177Lu of a specific activity in excess of
0.74 GBq/μg (20 Ci/mg). By the time of radiolabelling
the specific activity is around 0.555 GBq/μg (15 Ci/mg);
this, however, should not fall below 10 Ci/mg. In prac-
tice, a specific activity of 37 to 74 MBq (1–2 mCi)
177Lu per microgram of precursor is routinely achieved
and is accepted for clinical use [66].
Administration
During the administration of the radiopeptide, a physi-
cian must remain nearby. A resuscitation cart as well as
a trained emergency team must be available. The radio-
pharmaceutical should be diluted with saline to a final
volume ranging from 10 ml to 100 ml, depending on
the infusion system used. The radiopharmaceutical
should be administered via an indwelling catheter to
ensure safe intravenous administration and prevent para-
vascular infiltration, and should be administered over 10
to 30 min, depending on the infusion system used. The
radiopeptide may be coinfused with amino acid solution
via a three-way stopcock (“piggy-back”). The line
should be flushed with saline after completion of radio-
peptide infusion. PRRNT may reproduce the syndromes
of the respective functional tumours due to the sudden
massive release of the hormones and stimulation of their
corresponding receptors. The clinical manifestation is
dependent on the specific hormone involved. The fol-
lowing measures are therefore recommended. Vital signs
(at least blood pressure and pulse) should be monitored
before and after therapy infusion in symptomatic patients.
Therapeutic interventions should be undertaken to treat the
functional syndrome effects or exacerbation (e.g. carcinoid
syndrome/hypotension, hypoglycaemia, hypergastrinae-
mia, hypertension, hypotension, WDHA syndrome, elec-
trolyte imbalance). Nursing personnel must be instructed in
radiation safety. Any serious or life-threatening medical
condition should be noted and contingency plans put
in place in case radiation precautions need to be
breached to allow emergency medical care. In a medical
emergency, concerns about radiation exposure should
not hinder the prompt delivery of appropriate medical
care to the patient. During the first 2 days after PRRNT
the high levels of activity excretion in the urine is of
particular concern. Patients should be advised to observe
rigorous hygiene to avoid contaminating persons using
the same toilet facilities. A double toilet flush is rec-
ommended after urination. Patients should wash their
hands after urination. If contaminated with urine,
patients should wash their hands with abundant cold
water without scrubbing. Once discharged, patients
should be cautioned to avoid soiling underclothing or
areas around toilet bowls for 1 week following PRRNT.
Considerably contaminated clothing should be washed
separately. Incontinent patients should be catheterized
prior to PRRNT and the catheter should be kept for
2 days thereafter. Urine bags should be emptied fre-
quently. Gloves and protective clothing should be worn
by staff caring for catheterized patients (or providing
any care involving close contact). Women of childbear-
ing potential should use effective contraception while
undergoing treatment and avoid pregnancy for at least
6 months thereafter. Male patients should consider
sperm banking before therapy.
Treatment regimens for the noncompromised patient
90Y-DOTATATE / 90Y-DOTATOC
& Administered activity: 3.7 GBq (100 mCi)/m2 body
surface
& Number of cycles: two
& Time interval between cycles: 6–12 weeks or
& Administered activity: 2.78–4.44 GBq (75–120 mCi)
& Number of cycles: two to four
& Time interval between cycles: 6–12 weeks
177Lu-DOTATATE / 177Lu-DOTATOC
& Administered activity: 5.55–7.4 GBq (150–200 mCi)
& Number of cycles: three to five
& Time interval between cycles: 6–12 weeks
Combination 90Y/177Lu peptides Combination therapies
with 90Y and 177Lu peptides are being actively investigated
and may prove to be of additional therapeutic benefit. How-
ever, such combination treatments should be performed in
centres with sufficient competence and extensive experi-
ence. In this case administered activities should be adjusted
on an individual basis.
Sequential administration:
& 90Y administered activity: 2.5–5.0 GBq (68–135 mCi)
& 177Lu administered activity: 5.55–7.4 GBq (150–
200 mCi)
& Number of cycles: two to six
& Time interval between cycles: 6–16 weeks
Concurrent therapies, administering a cocktail of 177Lu
and 90Y peptides are also emerging.
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The compromised patient
For the compromised patient, the administered activity may
be reduced and treatment cycles are individualized with due
consideration to prevailing clinical and biochemical param-
eters, and the results of dosimetric studies.
In patients with reduced renal function the following
additional interventions are used:
(a) Nephrourology consultation.
(b) Extensive hydration (e.g. 2–3 l of fluid intake, if clin-
ically appropriate) prior to PRRNT.
(c) Diuretics (e.g. furosemide) should be considered in
case of dilated renal pelvis and delayed outflow.
(d) Whenever possible, consider the patient for 177Lu-
based treatments.
In patients with reduced haematological values the fol-
lowing additional interventions are used:
(a) Haematologist consultation.
(b) When required, packed red blood cells or platelet con-
centrate support may be given following PRRNT.
(c) If needed, growth factor support with granulocyte stim-
ulating factors or erythropoietin (or derivatives) can be
considered not earlier than 10 days after PRRNT.
(d) In patients with severely compromised bone marrow
reserves, peripheral stem cell harvesting as a precau-
tionary measure could be considered before PRRNT
and, if necessary, reinfusion could be performed after
an appropriate time from PPRNT has elapsed.
Special considerations for PRRNT in children
NETs and neural crest tumours in children express high
levels of sstrs and can potentially be treated with PRRNT.
With the exception of appendiceal carcinoid, most NETs in
children are metastatic at diagnosis. Children under the age
of 18 years have been excluded from participation in
PRRNT trials resulting in a lack of information on safety,
toxicity and efficacy in this age group. Conservatively,
absorbed doses to the kidney are limited to less than 21–
23 Gy. 90Y-DOTATOC has been used in children with
administered activities of 1.5–1.85 GBq/m2 per cycle for
up to three cycles [67]. With regard to the use of 177Lu-
DOTATATE in children, there is no widespread experience,
and activities should be adapted per square metre [68].
Retreatment options
The decision to re-treat a patient with PRRNT should only
be undertaken within the framework of the tumour board. In
patients who have previously responded to PRRNT, retreat-
ment may be considered in those with well-documented
disease progression and taking into account the total previ-
ous radiation dose to the kidneys and bone marrow. This
new PRRNT course will be subject to the same eligibility
criteria applied to the first radiopeptide treatment cycle. The
options include the use of the same or a different radio-
peptide. For instance, choosing 177Lu-labelled peptides may
be warranted, especially when considering the preservation
of kidney function. When designing a retreatment regimen,
due consideration should be given to the possibility of
exceeding the renal threshold dose especially in patients
with a good prognosis and expectation of long survival.
Using 177Lu-labelled peptides, whole-body imaging should
always be performed following each cycle to document the
distribution of the radiopharmaceutical and to evaluate the
functional response to PRRNT.
Dosimetry
Radiation dosimetry of normal organs and malignant lesions
provides an insight for optimizing the delivery PRRNT,
thereby allowing the dose delivered to the tumour to be
maximized while minimizing the dose delivered to normal
organs, particularly the kidney and bone marrow. If feasible,
patient-specific dosimetry can provide valuable information
to assess organ-specific radiation absorbed doses and to
assess the risk of delayed organ toxicity, particularly of the
kidneys and bone marrow in a patient with known risk
factors (see Table 1).
Different dosimetry methods, practical and sophisticated,
can be applied depending on final objective and availability
of resources. Input data include data from blood, urine, and
whole-body scans adequately scheduled up to at least 3 days
after PRRNT. Planar images are useful to derive biokinetics
over time, while SPECT and SPECT/CT fused images,
although requiring more time to acquire, provide insight
into organ-specific three-dimensional activity distribution.
The MIRD scheme provides reference techniques for inter-
nal dosimetry. Dedicated software (OLINDA/EXM) has
been used to derive mean absorbed dose estimates for
177Lu and 90Y peptides; [69, 70].
PRRNT dose estimates in organs are generally calculated
using the MIRD scheme, with the basic formula:
D ¼ eA S ¼ A0  t  S;
where Ã is the integral activity in the organ, A0 is the
initial activity in the organ, τ is the residence time
corresponding to the total number of decays occurring in the
organ divided by A0, and S is a dose conversion factor depend-
ing on the properties of the radionuclide and the target. The
value of S should be corrected for the actual volume and mass
of the organ. Once the integral activities in the organs of interest
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are determined using numerical or compartmental models [71,
72], absorbed doses are generally calculated using dedicated
software programs that use as input the residence time τ or the
number of decays (OLINDA/EXM, RADAR) [71, 72].
The typical kinetics of radiopeptides, namely very fast blood
clearance and renal elimination, determine the information
required to obtain the integral activities in organs and tumour,
which includes a whole dataset of scintigraphic images and data
from blood and urine samples. Once the rough data are ana-
lysed, the activity in normal and tumour tissues is converted
into time–activity curves for the calculation of absorbed dose
estimates. The residence time for the red marrow is calculated
from the residence time for blood, with the assumption that
nonspecific uptake of the radiolabel takes place in the bone
marrow. Uniform activity distribution and equivalent clearance
in red marrow and blood are assumed. Due to the small size of
the radiopeptide, the specific activity in bone marrow can be
considered equal to the specific activity in blood [73, 74].
Overall, the dose to the red marrow results from bone marrow
self-irradiation and the contribution from the remainder of the
body. Tumour absorbed doses can then be estimated by assum-
ing the lesion is a sphere and assuming a uniform activity
distribution [75, 76]. For 90Y-DOTATOC, the lack of γ-
emission by 90Y makes direct dosimetry quite difficult.
Bremsstrahlung images are rather difficult to quantify,
requiring the application of complex corrections. For this
reason two alternative options are used in clinical practice:
111In and 86Y simulations. Despite some drawbacks, the ex-
trapolated absorbed doses are reasonably similar. For dosimet-
ric purposes 111In-DOTATOC has been used in clinical
practice as a surrogate for 90Y-DOTATOC because of its
similar chemical and kinetic properties. An alternative but
far more demanding solution is to use DOTATOC labelled
with the positron emitter 86Y. PETwith 86Y-DOTATOC offers
improved spatial resolution and quantitative analysis. Never-
theless, the short time window for data collection (24–40 h),
as a consequence of the physical half-life (14.7 h) of 86Y, the
low positron abundance, the high production cost and the low
availability, are a challenge to the routine utilization of this
method. 111In-pentetreotide scintigraphy and PET with 68Ga-
DOTATOC are not suitable for accurate dosimetric calcula-
tion, the former due to its different kinetic behaviour and
receptor affinity profile and the latter due to the short physical
half-life (68 min) of 68Ga. Recently, a PET-based method
promising quantitative imaging of 90Y distribution was de-
scribed [76–78]. In the case of 177Lu-DOTATATE, the gamma
photons emission allows both imaging and dosimetry of the
same compound. Therefore dosimetry is usually performed
Table 1 Reported absorbed ra-
diation dose estimates following
PRRNT utilizing 90Y-DOTA-
TOC and 177Lu-DOTATATE.
Values are organ absorbed doses
per unit activity (Gy/GBq);
mean ± SD or median (range)
aDosimetry performed using
111In-octreotide (OctreoScan).
In all other investigations





Radiation dose Reference Radiation dose Reference
Red marrow 0.03±0.01 [75, 76] 0.07±0.01 [85]
0.17±0.02 [79] 0.04 (0.02–0.06) [86]
0.09 (0.03–0.18) [80] 0.04±0.02 [65]









3.7 (1.9–7.6) left; 4.3
(3.4–7.4) right
[84] 0.62 (0.45–17.74) [86]
3.84±2.02 (unprotected) [74, 76] 0.9±0.3 [65]





Liver 0.75±0.65 [74, 76] 0.18 (0.05–0.34) [86]
0.92±0.35 [79] 0.13–1.10 [87]





low burden, 2.67 high burden
[67]a
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Side effects of PRRNT are usually mild, if necessary precau-
tions are taken. Side effects may be acute, related to the
administration of amino acids or to the radiopeptide itself, or
chronic. The coinfusion of amino acids enlarges the safety
margin for treating with higher activities enabling higher
tumour radiation doses to be attained safely. Side effects such
as nausea, headache and rarely vomiting due to metabolic
acidosis induced by the amino acid coadministration do occur
in the majority of patients [59, 88]. Particular attention and
care should be given to avoiding possible electrolyte imbal-
ance (hyperkalaemia, hypernatraemia), and the subsequent
metabolic acidosis, that might lead to mild nausea and vomit-
ing. The latter side effects should bemanaged by hydrating the
patient with normal saline and possibly by repeating cortico-
steroid or antiemetic administrations.
PRRNT may exacerbate the syndromes related to the re-
spective functional tumours, due to the sudden massive re-
lease of the hormones and receptor stimulation. The clinical
manifestation is dependent on the specific hormone involved.
The following measures are therefore recommended. Vital
signs (at least blood pressure and pulse) should be monitored
before and after radiopeptide infusion, especially in symptom-
atic patients. Therapeutic interventions should be undertaken
to treat the for functional syndrome effects or exacerbation
(e.g. carcinoid syndrome/hypotension, hypoglycaemia, hyper-
gastrinaemia, hypertension, hypotension, WDHA syndrome,
electrolyte imbalance) [89]. In patients without or with minor
metastatic liver involvement, no significant hepatic toxicity
has been reported. However, in patients with massive liver
metastases and impaired liver function, liver toxicity may
occur, and this should be considered, along with preexisting
conditions affecting the liver, when choosing the appropriate
radioisotope and dosing. In such cases, 177Lu-labelled pepti-
des should be used and the administered activity should be
reduced accordingly. After treatment, patients should avoid
pregnancy for at least 6 months. Due to a temporary impair-
ment of fertility, related to a transient damage to Sertoli cells,
male patients should consider sperm banking before therapy.
Delayed side effects
Renal toxicity
The kidneys are the dose-limiting organs at the activities
normally reached with PRRNT. Proper kidney protection, as
discussed, is currently mandatory. However, despite kidney
protection, loss of kidney function can occur after PRRNT,
with a creatinine clearance loss of about 3.8 % per year for
177Lu-DOTATATE and 7.3 % per year for 90Y-DOTATOC
[90]. In a series of 1,109 patients treated with 90Y-DOTATOC,
the incidence of grade 4 and 5 kidney toxicity was found to be
9.2 % [50]. Delayed renal toxicity following 90Y-DOTATOC
treatment was observed more frequently in patients with pre-
disposing risk factors including longstanding and poorly con-
trolled hypertension and diabetes mellitus [56].
Bone marrow toxicity
Severe (grade 3 and 4), mostly reversible, acute bone mar-
row toxicity is observed in less than 10–13 % of treatment
cycles with 90Y-DOTATOC, and in 2–3 % of cycles with
177Lu-DOTATATE. Nevertheless, sporadic cases of myelo-
dysplastic syndrome or overt acute myelogenous leukaemia
have been reported [45, 49, 50].
Endocrine systems
Despite the presence of sstr in normal pituitary, thyroid and
adrenal glands and Langerhans cells, no significant alteration
in endocrine hormone function have been reported [91].
Results
PRRNT with the somatostatin analogues 90Y-DOTATOC
and 177Lu-DOTATATE has been explored in NET for more
than a decade. Present knowledge and clinical studies indi-
cate that it is possible to deliver tumoricidal absorbed doses
(e.g. >200 Gy) to neoplastic tumours expressing sst2 recep-
tors, leading to partial or complete objective responses in up
to 30 % of patients. The best objective responses have been
reported in gastroenteropancreatic NETs (with partial
responses ranging from 9 % to 29 % and complete remission
from 2 % to 6 %), and similar rates have been achieved in
thorax (lung) NETs and neuroectodermal tumours (phaeo-
chromocytomas, paragangliomas). Less favourable results
have been reported for thymic NETs, medullary thyroid
carcinoma and dedifferentiated thyroid carcinomas. Encour-
aging results have also been reported for sstr-positive
tumours including meningiomas, medulloblastomas and as-
trocytomas [45–55, 92, 93].
Survival analyses have shown that patients with high sstr
tumour expression at study entry, treated with either 177Lu-
DOTATATE or 90Y-DOTATOC, show significantly higher
objective responses that translate into significantly longer
survival [48, 50]. A favourable biochemical response was
also shown to be predictive of improved overall survival in
patients with medullary (calcitonin) and dedifferentiated
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iodide-negative thyroid cancer (thyroglobulin) undergoing
90Y-DOTATOC treatment [52, 54]. Symptomatic response,
particularly a durable improvement in diarrhoea after 90Y-
DOTATOC treatment, proved to have an impact on PFS
[49]. Initial data indicate that combination treatments with
the two isotopes 90Y and 177Lu linked either to DOTATOC
or to DOTATATE administered in sequential treatment
cycles or as a cocktail infusion for several cycles improve
survival [94, 95]. However, larger prospective randomized
trials are needed to confirm these results. In children and
young adults only one controlled clinical phase I trial of
PRRNT has been conducted utilizing 90Y-DOTATOC at
activity levels of 1.11, 1.48 and 1.85 GBq/m2 per cycle in
three cycles at 6-week intervals [67]. Three patients showed
a partial response, five a minor response, five stable disease
and two progressive disease. Dosimetry results were similar
to the dosimetry estimates in adults.
The evaluation of response to PRRNT includes the as-
sessment of functional and morphological responses, bio-
chemical and symptomatic responses, and quality of life.
Response is assessed by morphological and functional im-
aging techniques. Posttherapeutic 177Lu-DOTATATE scans
provide valuable information on the intensity of uptake and
localization of the tracer, and thus can be used to assess the
response to the prior therapy cycles. The time-line to assess
response may vary according to clinical needs (aggressive-
ness and extent of disease), but usually the first follow-up
examination is recommended after 3 months, and subse-
quent follow-up examinations should be performed after
3–6 months. The reader is also referred to the ENETS
guidelines for a more detailed discussion of the standards
of care in NET follow-up and documentation [96].
Follow-up
The assessment of renal function is of paramount importance,
as the kidney, together with the bone marrow, is the critical
organ in PRRNT. The follow-up should include the evaluation
of serum creatinine levels and the determination of creatinine
clearance. In patients with pre-existing risk factors for delayed
renal toxicity (high-risk group), in particular long-standing
and poorly controlled hypertension and diabetes mellitus,
single kidney or previously documented renal insult, mainly
nephrotoxic chemotherapy, more precise methods to assess
renal function are recommended. These techniques may in-
clude GFR measurements by means of 99mTc-DTPA, 51Cr-
EDTA or measurement of 99mTc-MAG3 clearance.
Between-cycle follow-up
A complete blood cell count should be performed every 2–
4 weeks. A higher frequency can be adopted if clinically
required. Renal and liver function tests should be available
before confirming subsequent cycles. Following careful
clinical assessment, patients with blood values lower than
the limits indicated for the first PRRNT cycle should receive
a lower activity and/or the interval to the following PRRNT
cycle should be extended. In severe cases, interruption of
PRRNT might be considered.
Intermediate and long-term follow-up
A complete blood cell count (including mean corpuscular
volume), and renal and liver function tests should be per-
formed every 8–12 weeks for the first 12 months, and
thereafter twice a year if clinically indicated. Evaluation of
response to treatment includes consideration of the clinical,
biochemical, morphological and PET/SPECT functional sta-
tus, and wellbeing of the patient. Morphological response is
determined by contrast-enhanced CT or MRI. Objective
response can be determined using the WHO, SWOG and
RECIST criteria [97–99]. For assessing morphological re-
sponse, CT is the preferred imaging technique, but this does
not rule out the use of MRI. In some patients, CT and MRI
may provide complimentary information. In any case, the
same imaging modality should be employed during the
follow-up of the individual patient. Depending on the dis-
ease duration and on tumour biology, these examinations are
repeated every 3–6 months, but may be extended up to once
every 12 months in the long-term follow-up in patients with
a durable response.
Functional imaging is a valuable instrument to assess the
course of the disease, and it has been demonstrated to be
able to predict morphological response. Combined function-
al and morphological imaging may in many cases better
reflect the true behaviour of the tumour following PRRNT.
Such imaging includes 111In-pentetreotide (OctreoScan)
and, if available, PET/CT with 68Ga-DOTA peptides or
metabolic monitoring with, for example, 18F-DOPA. How-
ever, functional imaging is not yet accepted as a substitute
for morphological imaging as a means to assess tumour
response to a treatment.
Disclaimer
This guidance document is a compilation of recent pub-
lished evidence on the use of PRRNT in NETs and the
personal experience of leading experts in the field reflecting
personal opinion based on unpublished data. It pays special
attention to and emphasizes gastroenteropancreatic presen-
tations. The guidance is not provided as an inflexible set of
rules and is not intended, nor should it be used, to establish
legal standards of care. For these reasons as well as those set
out below, this guidance should not be used in litigation in
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which the clinical decisions of practitioners are being called
into question.
The EANM and the IAEA have written and approved
guidelines to promote the cost-effective use of high-quality
nuclear medicine therapeutic procedures. These generic rec-
ommendations cannot be rigidly applied to all patients in all
practice settings. The guidelines should not be deemed
inclusive of all proper procedures or exclusive of other
procedures reasonably directed to obtaining the same
results. Advances in medicine occur at a rapid rate. The date
of a guideline should always be considered in determining
its current applicability.
Further reading
For additional reading, the book published by the Nuclear
Medicine Section, IAEA, entitled “Practical guidance on pep-
tide receptor radionuclide therapy (PRRNT) for neuroendo-
crine tumours” (Human Health Series no. 12) is available for
download using the link http://www.iaea.org/Publications/
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